Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559279 | 0.88 | NR4A2 (0.74) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL497746 | 0.85 | NR4A2 (0.78) | NR4A2CYP2A6MAPTCREBBPGABRA1 | |
| SCHEMBL30539775 | 0.85 | GABRA1 (0.56) | NR4A2MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL22445235 | 0.85 | GABRA1 (0.56) | NR4A2MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL6029944 | 0.84 | NR4A2 (0.73) | NR4A2MAPTCREBBPTUBB1 | |
| SCHEMBL6030601 | 0.82 | NR4A2 (0.51) | NR4A2MAPTCREBBPGABRA1GABRB1 | |
| SCHEMBL6334125 | 0.82 | NR4A2 (0.74) | NR4A2MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL6029910 | 0.82 | MAPT (0.66) | NR4A2MAPTGABRA1GABRB1GABRA3 | |
| SCHEMBL1557611 | 0.81 | CYP2A6 (0.50) | NR4A2CYP2A6 | |
| SCHEMBL6332786 | 0.81 | NPC1 (0.61) | NR4A2MAPTCREBBPTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | NR4A2 23/4885CYP2A6 1550/4885MAPT 3259/4885 |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | NR4A2 1135/4885CYP2A6 3148/4885MAPT 3228/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | NR4A2 2139/4885CYP2A6 4128/4885MAPT 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.